Equity
€17.2m ▲ 7.4%
KITOZYME has made a profit without a break since 2021.
KITOZYME
Lifetime
19 annual accounts with figures on one time axis, 25 filings since 2001peak €8.9m (2019)
€7.1m▲ 6.3%
lowest -€6.8m (2012)
€824,661▼ 24.9%
peak €17.2m (2025)
€17.2m▲ 7.4%
€4.8m▲ 3.6%
peak 54.7 FTE (2009)
27.2 FTE▼ 0.4%
Board14 names since 2017all names
5 directors and 4 others
Owners6 names in the annual accounts
44% and 3 others
Documentsfilings and deeds
02-07-202629 days before the deadline
2025abbreviated format
Investments €2.4mCash from €1.3m to €635,010
Key points
from the 2025 annual accountsInvestments
€1.7m 1.5 × depreciation
Green is investment, beige is depreciation. Machinery stands 24.7% higher than in 2024.
Staff
27.2 FTE from 54.7 in 2009
Between 2009 and 2025, 50% of the full-time equivalents disappeared.
Payment terms
25 days to suppliers
KITOZYME pays its suppliers 25 days earlier than in 2024. Customers pay 16 days earlier.
Filings
25 annual accounts since 2001
Two of the last ten came late. The 2021 accounts came latest: 862 days after the end of the period.
Position in the sector
€17.2m
More equity than 95% of companies in chemicals. Sector median €746,999 · 197 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 14,769 companies had the same profile as KITOZYME has now. Each dot stands for 37 companies, two years later.
96.2%
were still trading
3.5%
stopped another way
0.2%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 14,769 companies, not a prediction for KITOZYME. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 20-06-2025
Director,
Director, , since 20-06-2025
Director,
Director
Auditor,
- 44%score equity €8.8m (2025) · annual accounts 2025
- 18.48%equity €4.98bn (2025) · 2025 annual accounts of
- 18%equity €2.42bn (2022) · annual accounts 2025
Recent changes
5 directors reappointed, 1 statutory auditor reappointed
, , , , and (statutory auditor) · General meeting of 16-06-2026 · Gazette deed
3 directors reappointed
, and · Permanent representatives: , and · General meeting of 21-06-2024 · Gazette deed
1 director reappointed, 1 statutory auditor reappointed
Permanent representatives: , and · and (statutory auditor) · General meeting of 16-06-2023 · Gazette deed
1 director resigning, 2 reappointments
Permanent representatives: , and · Resignation: · Reappointments: and · General meeting of 17-06-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| KITOZYME Herstal | €7.1m | 9.4% | 76.9% | 27.2 |
| ENZYBEL INTERNATIONAL Villers-le-Bouillet | €9.2m | 2.8% | 77.4% | 24.9 |
| TransFurans Chemicals Geel | €15.1m | 5.3% | 73.0% | 43.7 |
| ARKEMA ANTWERP Brussels | €18.0m | 7.1% | 20.8% | 43.7 |
| SYSTEMHOUSE Mouscron | - | - | 55.2% | 15.3 |
| LUYTEN Namur | €12.1m | 4.8% | 68.6% | 23.3 |
| FAMENNE ENROBES Marche-en-Famenne | €11.3m | 2.4% | 42.9% | 12 |
Grey: the largest companies of the sector (chemicals (NACE 20)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as KITOZYME: manufacture of chemicals and chemical products (NACE 20140). They are comparable in size and age: total assets between €6.1m and €30m, founded between 1993 and 2009.
Official details
Source: KBO- Status
- Active since 02-01-2001Normal situation
- Activity
- Manufacture of chemicals and chemical productsNACE 20140
- Establishment unit
- 2.176.028.4174040 Herstal, since 01-06-2008
- Financial year end
- 31 December
- Peppol
- Reachable
Annual accounts 2025
- €22.4m▲ 6.3%
- Employeeson 31-12-2025
- 29▲ 7.4%
- Filing
- Filed on 02-07-2026, 29 days before the end of the filing period
Companies linked to KITOZYME
Shareholders
- 16%
Insights on KITOZYME
KITOZYME has existed since 2001. In 2009 turnover rose from €51,120 to €260,463.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about KITOZYME
- What is the company number of KITOZYME?
- The company number of KITOZYME is 0473.676.932. The VAT number is the same number with BE in front: BE 0473.676.932.
- Where is KITOZYME based?
- The registered office is at Rue de Milmort 680, 4040 Herstal.Company details
- What does KITOZYME do?
- According to the KBO register, the main activity is manufacture of chemicals and chemical products (NACE 20140).
- What is the legal form of KITOZYME?
- KITOZYME is a public limited company (NV).
- When was KITOZYME founded?
- KITOZYME was founded on 02-01-2001.
- Is KITOZYME still active?
- Yes, KITOZYME is an active enterprise in the KBO register.
- How many employees does KITOZYME have?
- KITOZYME had an average of 27.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of KITOZYME?
- The turnover of KITOZYME was €7.1m in financial year 2025, according to the filed annual accounts.
- Is KITOZYME profitable?
- In financial year 2025, KITOZYME made a profit of €824,661.
- Where can I find the annual accounts of KITOZYME?
- KITOZYME filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of KITOZYME due?
- KITOZYME must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.